MoneyGram International (NASDAQ:MGI)- Recommended Momentum ‘How’ and ‘Why’: Himax Technologies (NASDAQ:HIMX)

MoneyGram International, Inc. (NASDAQ:MGI) [Trend Analysis] luring active investment momentum, shares a loss -1.93% to $12.67. MoneyGram (MGI) and Ant Financial Services Group, a digital financial services provider and parent company of Alipay, a global mobile payment platform, reported they have entered into a definitive contract under which MoneyGram will merge with Ant Financial, with stockholders of MoneyGram being offered $13.25 per share in cash.

The transaction is valued at approximately $880 million for all of MoneyGram’s common and preferred shares on a fully diluted basis and Ant Financial will assume or refinance MoneyGram’s outstanding debt. The acquisition is expected to close in the second half of 2017. Upon completion of the transaction, MoneyGram will retain the MoneyGram brand name and management team.

Alex Holmes will continue to serve as Chief Executive Officer of MoneyGram. MoneyGram will remain headquartered in Dallas and is expected to maintain and grow its U.S.-based workforce. The total volume of 2.04 Million shares held in the session was surprisingly higher than its average volume of 440.74 shares.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at -212.50%, and looking further price to next year’s EPS is 30.06%. While take a short look on price to sales ratio, that was 0.45 and price to earnings ratio of 72.40 attracting passive investors.

Several matter pinch shares of Himax Technologies, Inc. (NASDAQ:HIMX) [Trend Analysis], as shares plunging -1.10% to $5.41 with a share volume of 2.78 Million. Himax Technologies, Inc. (HIMX) pre-reported preliminary unaudited financial results for the fourth quarter. The company noted that gross margin and earnings per share for the fourth quarter missed its guidance due to an additional inventory write-down. However, revenues for the quarter were in-line with its outlook.

The latest quarter’s results include a non-cash inventory write-down totaling $12.0 million. After the write-down, earnings per ADS for the fourth quarter were 2.6 cents, below the company’s guided range of 8.5 to 11.0 cents. Adjusted earnings per ADS were 2.8 cents, below the company’s guided range of 8.7 to 11.2 cents. Excluding the additional inventory write-down, declared and adjusted earnings per share would have been 8.6 cents and 8.8 cents, respectively and met the company’s original guidance.

The stock is going forward its 52-week low with 1.69% and moving down from its 52-week high price with -54.27%. To have technical analysis views, liquidity ratio of a company was calculated 2.00 as evaluated with its debt to equity ratio of 0.31. The float short ratio was 7.67%, as compared to sentiment indicator; Short Ratio was 3.22.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *